For motor fluctuations specifically, options include increasing the dose of levodopa, using controlled release levodopa, adjunctive therapy with a dopamine agonist, or using subcutaneous apormorphine for rescue.
In this study, the sub-acute toxicity of oral zinc aluminium nanocomposite with and without levodopa was assessed using the Organization for Economic Co-operation and Development guidelines.
Analysis with regard to group difference in time from diagnosis until start of levodopa was analyzed using the Mann–Whitney U test.
For example, protein and vitamin B6 interfere with the effectiveness of levodopa, used to treat Parkinson disease.
Treatment of PD is primarily based on DA replacement using the dopamine pro-drug, levodopa (L-DOPA).
Given the relative frequency of vitamin B12 deficiency in the elderly [39], [40], our data suggest a further evaluation of the cellular, tissular and functional consequences of Levodopa in case of B12 deficiency, using the TCII-OLEO cells and our model of transfected rat with Parkinson-like phenotype.
Levodopa equivalent daily dose value was calculated using the Tomlinson et al. (2010) formula.
Possible differences in age, age of onset, disease duration, time between start of levodopa and the development of dyskinesias, years of levodopa use, and the unified Parkinson's disease rating scale (UPDRS) motor scores were analyzed using the independent t test.
Using the pharmacokinetic data from LCIG phase 1 and 3 clinical studies, this analysis compared levodopa bioavailability and the intra-subject variability in levodopa plasma concentrations for the two methods of administration in the target patient population.
Toxicity result using the nanodelivery technique on cell line in the same study was demonstrated to be reduced compared to pure levodopa.
